The Alzheimer's Association reports that PrecivityAD2 was FDA-cleared on Aug. 20, 2026 to aid Alzheimer's diagnosis in symptomatic adults age 40 and older, in the FDA clearance notice.
For younger-onset families, that means amyloid evidence can enter care sooner, while planning still centers on confirming results, work, safety, and treatment. PrecivityAD2 is a blood test that measures amyloid-beta and tau markers and reports an Amyloid Probability Score 2 as negative, positive, or likely positive. Younger-onset Alzheimer's means disease starting before age 65, when symptoms often overlap with midlife health and work stress.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Why does age 40 change the workup?
- How is the result reported?
- How accurate is it, and where is caution needed?
- Why do younger adults still face delays?
- What can families do next?
Why does age 40 change the workup?
Medical News Today reports PrecivityAD2 was the third FDA-cleared Alzheimer's blood test, after tests limited to ages 55 and older. That age limit left many younger symptomatic adults outside blood-test eligibility. The new clearance lowers the eligible age to 40 for people with cognitive symptoms.
For families, the practical change is timing. A 48-year-old with progressive memory loss can now have blood biomarker data considered earlier in evaluation. The test does not replace history, exams, or cognitive testing. It adds one biological signal to clinical assessment.
How is the result reported?
NeurologyLive reports PrecivityAD2 uses high-resolution mass spectrometry to measure plasma amyloid-beta 42/40 ratio and p-tau217/np-tau217. The two ratios are combined into Amyloid Probability Score 2. The report gives one of three categories: negative, positive, or likely positive.
Negative points against brain amyloid pathology. Positive points toward it. Likely positive is intermediate and needs more context, not a final answer by itself.
How accurate is it, and where is caution needed?
C2N Diagnostics reported via BioSpace that a 1,142-person study in symptomatic adults found 97.6% positive predictive value and 93.1% negative predictive value versus amyloid PET visual read or CSF biomarkers, in the validation summary. Those values describe agreement with PET or spinal-fluid markers in that study population. They do not mean the blood test alone diagnoses dementia cause.
NeurologyLive reports about 17.3% of validation patients received likely-positive results with only 77.3% positive predictive value. That subgroup still needs PET, CSF, or clinical follow-up. The Alzheimer's Association guideline reported by Medical Laboratory Observer in 2025 permits qualified blood tests as triage or confirmatory tools in cognitively impaired patients, with interpretation alongside clinical assessment.
Why do younger adults still face delays?
AJMC reports younger-onset Alzheimer's affects people under 65, an estimated 200,000 Americans, and symptoms are often first attributed to depression, burnout, sleep loss, or menopause, in the younger-onset overview. That misattribution can delay tailored safety planning, work planning, and early-stage treatment discussion. A blood result does not fix that pattern by itself.
Clinicians still need a timeline of change at work and home. Examples include missed deadlines, lost steps in familiar tasks, getting lost, unsafe driving, or difficulty managing money and medications. A family account of change over months often matters as much as any single score.
What can families do next?
Start with a focused visit for cognitive symptoms, not a general checkup. Bring a written timeline, current medications, sleep and mood changes, and examples from work or daily tasks. C2N Diagnostics announced that starting Oct.
1, 2026, Anthem Blue Cross and Blue Shield covers PrecivityAD2 under medical policy for eligible members being evaluated for Alzheimer's, in the coverage announcement. Families should still confirm personal eligibility, referral rules, and lab handling before testing. Bring the symptom timeline, medication list, and work-duty examples to that visit.
- Note when symptoms began and what has worsened
- List safety concerns: driving, cooking, tools, finances, caregiving duties
- List work effects: errors, slower output, missed meetings, leave options
- Ask whether PrecivityAD2 fits, what a likely-positive result would trigger, and what PET or CSF access looks like locally
You Might Also Like
- The Third FDA-Cleared Alzheimer’s Blood Biomarker Test in 2026: What Changed and What Comes Next for Younger-Onset Alzheimer’s Families
- PrecivityAD2 as an Adjunct to a 2026 Alzheimer’s Assessment: What Changed and What Comes Next for Younger-Onset Alzheimer’s Families
- FDA’s 2026 PrecivityAD2 Alzheimer’s Blood Test Clearance: What Changed and What Comes Next for Younger-Onset Alzheimer’s Families
